| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11052061 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10952986 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11602513 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11602512 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10736866 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10272062 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11766418 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11000498 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11400065 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Jul, 2037
(13 years from now) | |
| US11826335 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11839597 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11065224 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10973795 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US11504347 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Jul, 2037
(13 years from now) | |
| US10925844 | AVADEL CNS | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
Feb, 2040
(15 years from now) | |
| US11583510 | AVADEL CNS | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Feb, 2042
(17 years from now) | |
| US11779557 | AVADEL CNS | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Mar, 2042
(17 years from now) | |
Lumryz is owned by Avadel Cns.
Lumryz contains Sodium Oxybate.
Lumryz has a total of 17 drug patents out of which 0 drug patents have expired.
Lumryz was authorised for market use on 01 May, 2023.
Lumryz is available in for suspension, extended release;oral dosage forms.
Lumryz can be used as treatment of narcolepsy and associated disorders and symptoms using a composition comprising gamma-hydroxybutyrate once daily, treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy who have an apnea/hypopnea index ≤15 with a once-nightly formulation of gamma-hydroxybutyrate, treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a once-daily pharmaceutical formulation comprising an oxybate, treatment of a disorder treatable with gamma-hydroxybutyrate using a single, daily dose of a gamma-hydroxybutyrate formulation, treatment of narcolepsy using a dose proportional, oral pharmaceutical composition comprising gamma-hydroxybutyrate once daily, treatment of narcolepsy-related cataplexy or excessive daytime sleepiness using a single daily, bedtime dose of a gamma-hydroxybutyrate formulation, treatment of cataplexy or excessive daytime sleepiness in patients with narcolepsy with a once-nightly gamma-hydroxybutyrate formulation, treatment of narcolepsy, cataplexy or excessive daytime sleepiness using a once-nightly gamma-hydroxybutyrate formulation.
The generics of Lumryz are possible to be released after 16 March, 2042.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-431) | May 01, 2030 |
| New Product(NP) | May 01, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 01 May, 2023
Treatment: Treatment of a disorder treatable with gamma-hydroxybutyrate using a single, daily dose of a gamma-hydroxybutyrate formulation; Treatment of narcolepsy-related cataplexy or excessive daytime sleepines...
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
LUMRYZ family patents
